Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease

BackgroundNon-Alcoholic Fatty Liver Disease, recently better recognised as Metabolic Dysfunction–Associated Steatotic Liver Disease, is the most prevalent form of chronic liver disease at present time. It is estimated to impact 32% of the world's population, hence representing a significant hea...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Liver Journal 2024-11, Vol.14 (1), p.80-13
Main Authors: ElGhandour, Ahmed Mohamed, Teama, Nahla Mohamed, Kamal, Marwa Abdullah, Nashaat, Ehab Hassan, Ghani, Amani Mohamed Abdel, Abdo, Ahmad Abbas
Format: Article
Language:English
Subjects:
Abdomen
Alcohol
Biomarkers
Body mass index
Diabetes
Diagnostic
Hepatology
Internal medicine
Liver diseases
Males
MASLD
Metabolic Dysfunction–Associated Steatotic Liver Disease
Metabolism
Non-Alcoholic Fatty Liver Disease
Plasma
Plasma Lipocalin-2 Levels
Prognostic
Software
Ultrasonic imaging
Variance analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 13
container_issue 1
container_start_page 80
container_title Egyptian Liver Journal
container_volume 14
creator ElGhandour, Ahmed Mohamed
Teama, Nahla Mohamed
Kamal, Marwa Abdullah
Nashaat, Ehab Hassan
Ghani, Amani Mohamed Abdel
Abdo, Ahmad Abbas
description BackgroundNon-Alcoholic Fatty Liver Disease, recently better recognised as Metabolic Dysfunction–Associated Steatotic Liver Disease, is the most prevalent form of chronic liver disease at present time. It is estimated to impact 32% of the world's population, hence representing a significant health burden.Aim of the workTo assess the significance of plasma Lipocalin-2 (LCN2) levels in the diagnosis and prognosis of NAFLD patients.Patients and methodsIn this retrospective case–control study we recruited 102 subjects aged between 18 and 70 years. The included participants were split into two study groups. Group I: 51 NAFLD patients (61% men, 39% females) and Group II: 51 healthy controls (51% men and 49% females), for whom plasma LCN2 levels were assessed and correlated with NAFLD fibrosis score, FIB4 and fatty liver index.ResultsIn this study, LCN2 levels in NAFLD patients were significantly greater compared to individuals in the control group (p 
doi_str_mv 10.1186/s43066-024-00387-8
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_journals_3124188939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b67930fbc7a743ca9e28787cde72433c</doaj_id><sourcerecordid>3124188939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-a6e28cd00c8bdf51f1860d95b756e11b8b39a76e1f77a09836e8745472d36e173</originalsourceid><addsrcrecordid>eNo9UMtOwzAQjBBIVMAPcLLEOeBHajtHVF6VkLjAOdrYm-LKjUPsFvXGkTt_yJdgKLCXnVlpZ0ZTFKeMnjOm5UWsBJWypLwqKRValXqvmHBa01JyLvf_MdOHxUmMS5pHM0WFmhTvVw4WfYjJGQK9JcMY_ugG_BpJ6MjgIa6AeDcEA971JSceN-gjcT0ZIDnsUySvLj2TFSZog8_fdhu7dW-SC_3n2wfEGIyDhJbEhJDCt4F3GxyJdREh4nFx0IGPePK7j4qnm-vH2V15_3A7n13el0YwmkqQyLWxlBrd2m7KulwAtfW0VVOJjLW6FTWoDDulgNZaSNSqmlaK2wyZEkfFfKdrAyybYXQrGLdNANf8HMK4aGDM6Tw2rVS1oF1rFKhKGKiztdLKWFS8EsJkrbOdVm7tZY0xNcuwHvscvxGMV0zrWtTiC8owgXw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3124188939</pqid></control><display><type>article</type><title>Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease</title><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><source>Publicly Available Content (ProQuest)</source><creator>ElGhandour, Ahmed Mohamed ; Teama, Nahla Mohamed ; Kamal, Marwa Abdullah ; Nashaat, Ehab Hassan ; Ghani, Amani Mohamed Abdel ; Abdo, Ahmad Abbas</creator><creatorcontrib>ElGhandour, Ahmed Mohamed ; Teama, Nahla Mohamed ; Kamal, Marwa Abdullah ; Nashaat, Ehab Hassan ; Ghani, Amani Mohamed Abdel ; Abdo, Ahmad Abbas</creatorcontrib><description>BackgroundNon-Alcoholic Fatty Liver Disease, recently better recognised as Metabolic Dysfunction–Associated Steatotic Liver Disease, is the most prevalent form of chronic liver disease at present time. It is estimated to impact 32% of the world's population, hence representing a significant health burden.Aim of the workTo assess the significance of plasma Lipocalin-2 (LCN2) levels in the diagnosis and prognosis of NAFLD patients.Patients and methodsIn this retrospective case–control study we recruited 102 subjects aged between 18 and 70 years. The included participants were split into two study groups. Group I: 51 NAFLD patients (61% men, 39% females) and Group II: 51 healthy controls (51% men and 49% females), for whom plasma LCN2 levels were assessed and correlated with NAFLD fibrosis score, FIB4 and fatty liver index.ResultsIn this study, LCN2 levels in NAFLD patients were significantly greater compared to individuals in the control group (p &lt; 0.001), with a mean of 1893.214 ± 1002.852 ng/dL in the cases and a mean of 466.020 ± 397.699 ng/dL in the controls. This suggests the use of LCN2 as a possible diagnostic marker of NAFLD. The mean LCN2 levels in this study also significantly increased as the grade of fatty liver increased from I to III (p &lt; 0.001). This in turn proposes the use of LCN2 as a prognostic marker for NAFLD progression. LCN2 also significantly correlated with the fatty liver index and NAFLD Fibrosis scoring systems, but not with Fib-4. With an area under the ROC of 0.906, it demonstrated excellent diagnostic performance with 84% sensitivity, 90% specificity, 89.6% PPV and 85.2% NPV for the prediction of NAFLD patients.ConclusionLipocalin-2 performs as a diagnostic and a possible prognostic marker for metabolic dysfunction-associated steatotic liver disease.</description><identifier>ISSN: 2090-6218</identifier><identifier>EISSN: 2090-6226</identifier><identifier>DOI: 10.1186/s43066-024-00387-8</identifier><language>eng</language><publisher>Menoufiya: Springer Nature B.V</publisher><subject>Abdomen ; Alcohol ; Biomarkers ; Body mass index ; Diabetes ; Diagnostic ; Hepatology ; Internal medicine ; Liver diseases ; Males ; MASLD ; Metabolic Dysfunction–Associated Steatotic Liver Disease ; Metabolism ; Non-Alcoholic Fatty Liver Disease ; Plasma ; Plasma Lipocalin-2 Levels ; Prognostic ; Software ; Ultrasonic imaging ; Variance analysis</subject><ispartof>Egyptian Liver Journal, 2024-11, Vol.14 (1), p.80-13</ispartof><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3124188939/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3124188939?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>ElGhandour, Ahmed Mohamed</creatorcontrib><creatorcontrib>Teama, Nahla Mohamed</creatorcontrib><creatorcontrib>Kamal, Marwa Abdullah</creatorcontrib><creatorcontrib>Nashaat, Ehab Hassan</creatorcontrib><creatorcontrib>Ghani, Amani Mohamed Abdel</creatorcontrib><creatorcontrib>Abdo, Ahmad Abbas</creatorcontrib><title>Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease</title><title>Egyptian Liver Journal</title><description>BackgroundNon-Alcoholic Fatty Liver Disease, recently better recognised as Metabolic Dysfunction–Associated Steatotic Liver Disease, is the most prevalent form of chronic liver disease at present time. It is estimated to impact 32% of the world's population, hence representing a significant health burden.Aim of the workTo assess the significance of plasma Lipocalin-2 (LCN2) levels in the diagnosis and prognosis of NAFLD patients.Patients and methodsIn this retrospective case–control study we recruited 102 subjects aged between 18 and 70 years. The included participants were split into two study groups. Group I: 51 NAFLD patients (61% men, 39% females) and Group II: 51 healthy controls (51% men and 49% females), for whom plasma LCN2 levels were assessed and correlated with NAFLD fibrosis score, FIB4 and fatty liver index.ResultsIn this study, LCN2 levels in NAFLD patients were significantly greater compared to individuals in the control group (p &lt; 0.001), with a mean of 1893.214 ± 1002.852 ng/dL in the cases and a mean of 466.020 ± 397.699 ng/dL in the controls. This suggests the use of LCN2 as a possible diagnostic marker of NAFLD. The mean LCN2 levels in this study also significantly increased as the grade of fatty liver increased from I to III (p &lt; 0.001). This in turn proposes the use of LCN2 as a prognostic marker for NAFLD progression. LCN2 also significantly correlated with the fatty liver index and NAFLD Fibrosis scoring systems, but not with Fib-4. With an area under the ROC of 0.906, it demonstrated excellent diagnostic performance with 84% sensitivity, 90% specificity, 89.6% PPV and 85.2% NPV for the prediction of NAFLD patients.ConclusionLipocalin-2 performs as a diagnostic and a possible prognostic marker for metabolic dysfunction-associated steatotic liver disease.</description><subject>Abdomen</subject><subject>Alcohol</subject><subject>Biomarkers</subject><subject>Body mass index</subject><subject>Diabetes</subject><subject>Diagnostic</subject><subject>Hepatology</subject><subject>Internal medicine</subject><subject>Liver diseases</subject><subject>Males</subject><subject>MASLD</subject><subject>Metabolic Dysfunction–Associated Steatotic Liver Disease</subject><subject>Metabolism</subject><subject>Non-Alcoholic Fatty Liver Disease</subject><subject>Plasma</subject><subject>Plasma Lipocalin-2 Levels</subject><subject>Prognostic</subject><subject>Software</subject><subject>Ultrasonic imaging</subject><subject>Variance analysis</subject><issn>2090-6218</issn><issn>2090-6226</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNo9UMtOwzAQjBBIVMAPcLLEOeBHajtHVF6VkLjAOdrYm-LKjUPsFvXGkTt_yJdgKLCXnVlpZ0ZTFKeMnjOm5UWsBJWypLwqKRValXqvmHBa01JyLvf_MdOHxUmMS5pHM0WFmhTvVw4WfYjJGQK9JcMY_ugG_BpJ6MjgIa6AeDcEA971JSceN-gjcT0ZIDnsUySvLj2TFSZog8_fdhu7dW-SC_3n2wfEGIyDhJbEhJDCt4F3GxyJdREh4nFx0IGPePK7j4qnm-vH2V15_3A7n13el0YwmkqQyLWxlBrd2m7KulwAtfW0VVOJjLW6FTWoDDulgNZaSNSqmlaK2wyZEkfFfKdrAyybYXQrGLdNANf8HMK4aGDM6Tw2rVS1oF1rFKhKGKiztdLKWFS8EsJkrbOdVm7tZY0xNcuwHvscvxGMV0zrWtTiC8owgXw</recordid><startdate>20241105</startdate><enddate>20241105</enddate><creator>ElGhandour, Ahmed Mohamed</creator><creator>Teama, Nahla Mohamed</creator><creator>Kamal, Marwa Abdullah</creator><creator>Nashaat, Ehab Hassan</creator><creator>Ghani, Amani Mohamed Abdel</creator><creator>Abdo, Ahmad Abbas</creator><general>Springer Nature B.V</general><general>SpringerOpen</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20241105</creationdate><title>Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease</title><author>ElGhandour, Ahmed Mohamed ; Teama, Nahla Mohamed ; Kamal, Marwa Abdullah ; Nashaat, Ehab Hassan ; Ghani, Amani Mohamed Abdel ; Abdo, Ahmad Abbas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-a6e28cd00c8bdf51f1860d95b756e11b8b39a76e1f77a09836e8745472d36e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abdomen</topic><topic>Alcohol</topic><topic>Biomarkers</topic><topic>Body mass index</topic><topic>Diabetes</topic><topic>Diagnostic</topic><topic>Hepatology</topic><topic>Internal medicine</topic><topic>Liver diseases</topic><topic>Males</topic><topic>MASLD</topic><topic>Metabolic Dysfunction–Associated Steatotic Liver Disease</topic><topic>Metabolism</topic><topic>Non-Alcoholic Fatty Liver Disease</topic><topic>Plasma</topic><topic>Plasma Lipocalin-2 Levels</topic><topic>Prognostic</topic><topic>Software</topic><topic>Ultrasonic imaging</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ElGhandour, Ahmed Mohamed</creatorcontrib><creatorcontrib>Teama, Nahla Mohamed</creatorcontrib><creatorcontrib>Kamal, Marwa Abdullah</creatorcontrib><creatorcontrib>Nashaat, Ehab Hassan</creatorcontrib><creatorcontrib>Ghani, Amani Mohamed Abdel</creatorcontrib><creatorcontrib>Abdo, Ahmad Abbas</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Egyptian Liver Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ElGhandour, Ahmed Mohamed</au><au>Teama, Nahla Mohamed</au><au>Kamal, Marwa Abdullah</au><au>Nashaat, Ehab Hassan</au><au>Ghani, Amani Mohamed Abdel</au><au>Abdo, Ahmad Abbas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease</atitle><jtitle>Egyptian Liver Journal</jtitle><date>2024-11-05</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>80</spage><epage>13</epage><pages>80-13</pages><issn>2090-6218</issn><eissn>2090-6226</eissn><abstract>BackgroundNon-Alcoholic Fatty Liver Disease, recently better recognised as Metabolic Dysfunction–Associated Steatotic Liver Disease, is the most prevalent form of chronic liver disease at present time. It is estimated to impact 32% of the world's population, hence representing a significant health burden.Aim of the workTo assess the significance of plasma Lipocalin-2 (LCN2) levels in the diagnosis and prognosis of NAFLD patients.Patients and methodsIn this retrospective case–control study we recruited 102 subjects aged between 18 and 70 years. The included participants were split into two study groups. Group I: 51 NAFLD patients (61% men, 39% females) and Group II: 51 healthy controls (51% men and 49% females), for whom plasma LCN2 levels were assessed and correlated with NAFLD fibrosis score, FIB4 and fatty liver index.ResultsIn this study, LCN2 levels in NAFLD patients were significantly greater compared to individuals in the control group (p &lt; 0.001), with a mean of 1893.214 ± 1002.852 ng/dL in the cases and a mean of 466.020 ± 397.699 ng/dL in the controls. This suggests the use of LCN2 as a possible diagnostic marker of NAFLD. The mean LCN2 levels in this study also significantly increased as the grade of fatty liver increased from I to III (p &lt; 0.001). This in turn proposes the use of LCN2 as a prognostic marker for NAFLD progression. LCN2 also significantly correlated with the fatty liver index and NAFLD Fibrosis scoring systems, but not with Fib-4. With an area under the ROC of 0.906, it demonstrated excellent diagnostic performance with 84% sensitivity, 90% specificity, 89.6% PPV and 85.2% NPV for the prediction of NAFLD patients.ConclusionLipocalin-2 performs as a diagnostic and a possible prognostic marker for metabolic dysfunction-associated steatotic liver disease.</abstract><cop>Menoufiya</cop><pub>Springer Nature B.V</pub><doi>10.1186/s43066-024-00387-8</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-6218
ispartof Egyptian Liver Journal, 2024-11, Vol.14 (1), p.80-13
issn 2090-6218
2090-6226
language eng
recordid cdi_proquest_journals_3124188939
source Springer Nature - SpringerLink Journals - Fully Open Access ; Publicly Available Content (ProQuest)
subjects Abdomen
Alcohol
Biomarkers
Body mass index
Diabetes
Diagnostic
Hepatology
Internal medicine
Liver diseases
Males
MASLD
Metabolic Dysfunction–Associated Steatotic Liver Disease
Metabolism
Non-Alcoholic Fatty Liver Disease
Plasma
Plasma Lipocalin-2 Levels
Prognostic
Software
Ultrasonic imaging
Variance analysis
title Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A41%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20prognostic%20value%20of%20plasma%20lipocalin-2%20levels%20in%20patients%20with%20metabolic%20dysfunction%E2%80%93associated%20steatotic%20liver%20disease&rft.jtitle=Egyptian%20Liver%20Journal&rft.au=ElGhandour,%20Ahmed%20Mohamed&rft.date=2024-11-05&rft.volume=14&rft.issue=1&rft.spage=80&rft.epage=13&rft.pages=80-13&rft.issn=2090-6218&rft.eissn=2090-6226&rft_id=info:doi/10.1186/s43066-024-00387-8&rft_dat=%3Cproquest_doaj_%3E3124188939%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c310t-a6e28cd00c8bdf51f1860d95b756e11b8b39a76e1f77a09836e8745472d36e173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3124188939&rft_id=info:pmid/&rfr_iscdi=true